Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2015

View Archived Issues

Athersys and Chugai sign Japanese agreement for MultiStem in ischemic stroke

FDA approves Liletta to prevent pregnancy for up to three years

GSK/Novartis transaction complete

Cardinal Health offers to acquire Cordis from Johnson & Johnson

FDA grants breakthrough therapy designation to Epstein-Barr virus targeted T cells

SBIR supports collaborative work in brain cancer between Nascent Biotech and Mapp Biopharmaceutical

Multiplatform tumor profiling shows potential for therapeutic decision-making

Dilafor releases results from safety and pharmacokinetic study of tafoxiparin

Anticoagulant-reversing agent andexanet alfa given FDA orphan drug status

Alkermes highlights new drug candidate, ALKS-7119

Alize Pharma begins phase II trial of AZP-531 in Prader-Willi syndrome

Lupin patents CaSR modulators

Constellation Pharmaceuticals reports development of EZH2 inhibitors

British investigators prepare new oligomers for muscular dystrophy

Resilience and PsychoGenics form drug discovery partnership

Celimmune enters into licensing and option agreement with Amgen to develop AMG-714

Mast Therapeutics reports data from nonclinical study of vepoloxamer in advanced heart failure

Clearside Biomedical begins phase II trial of CLS-TA in macular edema

FIOCRUZ patents new compounds for respiratory inflammatory diseases

Merck KGaA reports new tankyrase inhibitors

Denovo Biopharma licenses Lilly's pomaglumetad methionil

Pulmokine secures funding for phase I trial of PDGF receptor kinase inhibitor PK-10571

Prevenar 13 approved in E.U. for prevention of pneumococcal pneumonia in adults

Novel means of blocking Ebola entry into cells with existing agents identified

PSMA antibody-drug conjugate shows potential for the treatment of prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...